Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Neurology Rheumatology Diabetes / Metabolic Mental Health / Psychiatry Women's Health Dermatology Men's Health Rare Diseases
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1003 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1003 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

active not recruiting Phase III Oncology
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
Osimertinib after surgery improves survival in early-stage lung cancer patients with specific EGFR mutations.
23 Apr 2026 NCT05120349
active not recruiting Phase II / Phase III
A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)
Mitapivat tested in sickle cell patients to increase haemoglobin levels and reduce painful crisis episodes compared to placebo.
23 Apr 2026 NCT05031780
● Recruiting Phase III Gastroenterology
A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis
Trial testing a new drug (Afimkibart) for treating moderate-to-severe ulcerative colitis in children, measuring safety and effectiveness.
23 Apr 2026 NCT07158242
● Recruiting Phase III Respiratory / COPD / Asthma
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
What is being tested: Depemokimab, a monoclonal antibody, is being evaluated for its effects on airway structure and function in asthma patients using imaging…
23 Apr 2026 NCT06979323
● Recruiting Phase III Oncology
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Treatment being tested: Sonrotoclax (a BCL2 inhibitor) combined with zanubrutinib (a BTK inhibitor) versus placebo plus zanubrutinib alone in adults with relapsed/refractory mantle cell…
23 Apr 2026 NCT06742996
● Recruiting Phase III Oncology
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
What is being tested: Sacituzumab tirumotecan (an antibody-drug conjugate targeting Trop-2) compared against standard chemotherapy (docetaxel or pemetrexed) in previously-treated advanced/metastatic nonsquamous NSCLC patients…
23 Apr 2026 NCT06074588
● Recruiting Phase III Oncology
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Treatment being tested: Durvalumab combined with domvanalimab (a novel anti-CTLA-4 immune checkpoint inhibitor) versus durvalumab alone, given after concurrent chemoradiation in patients with unresectable…
23 Apr 2026 NCT05211895
active not recruiting Phase III
Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
Imlifidase allows highly sensitized kidney transplant patients with positive crossmatch to receive transplants safely, with good one-year graft survival.
22 Apr 2026 NCT05369975
● Recruiting Phase III Mental Health / Psychiatry
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
New psilocin-based drug CYB003 tested against placebo for treating depression as an add-on therapy.
22 Apr 2026 NCT06793397
active not recruiting Phase III
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Ianalumab added to steroids didn't improve platelet counts better than steroids alone in newly diagnosed ITP patients.
22 Apr 2026 NCT05653349
● Recruiting Phase III Oncology
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
Drug being tested: GSK5764227 (Risvutatug rezetecan/Ris-Rez) is a novel B7-H3-targeted therapy designed to inhibit cancer cell growth and metastasis in patients with relapsed small…
22 Apr 2026 NCT07099898
● Recruiting Phase III Cardiology / Cardiovascular
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial – Part 2
What is being tested: Recombinant Factor VIIa (rFVIIa) as a potential therapeutic intervention to halt hematoma expansion and improve outcomes in patients with acute…
22 Apr 2026 NCT07227246
● Recruiting Phase III Cardiology / Cardiovascular
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
What is being tested: ADX-324, a novel therapeutic agent, is being evaluated in a Phase 3 trial to assess its efficacy and safety in…
22 Apr 2026 NCT06960213
● Recruiting Phase III Oncology
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
What is being tested: BGB-16673, a novel BTK inhibitor, is being evaluated against pirtobrutinib (an established BTK inhibitor) in patients with relapsed/refractory CLL or…
22 Apr 2026 NCT06973187
● Recruiting Phase III Oncology
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
What is being tested: This Phase 3 trial compares belantamab mafodotin combined with lenalidomide and dexamethasone (BRd) against daratumumab combined with lenalidomide and dexamethasone…
22 Apr 2026 NCT06679101
● Recruiting Phase III Oncology
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Treatment being tested: IMVT-1402, a novel therapeutic agent, is being evaluated for efficacy, safety and tolerability in adults with generalized myasthenia gravis across mild…
22 Apr 2026 NCT07039916
● Recruiting Phase III Oncology
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
What is being tested: Zanubrutinib (a Bruton tyrosine kinase inhibitor) combined with obinutuzumab (anti-CD20 monoclonal antibody) versus the standard regimen of lenalidomide plus rituximab…
22 Apr 2026 NCT05100862
● Recruiting Phase III Oncology
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
What is being tested: A novel oral cladribine formulation is being evaluated against placebo for efficacy and safety in treating generalized myasthenia gravis (gMG),…
22 Apr 2026 NCT06463587
● Recruiting Phase III Oncology
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR – HN1)
Treatment being tested: Petosemtamab (a fibroblast activation protein inhibitor) combined with pembrolizumab compared to pembrolizumab monotherapy as first-line treatment for recurrent or metastatic head…
22 Apr 2026 NCT06525220
● Recruiting Phase III
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
A new drug (claseprubart) tested against placebo in adults with chronic inflammatory demyelinating polyneuropathy to assess whether it works and is safe.
21 Apr 2026 NCT06858579
active not recruiting Phase III
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
ALXN1720 (a complement inhibitor) was tested for safety and effectiveness in treating autoimmune myasthenia gravis in adults.
21 Apr 2026 NCT05556096
● Recruiting Phase III
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Anifrolumab injection added to standard treatment improved muscle disease activity in adults with polymyositis and dermatomyositis compared to placebo.
21 Apr 2026 NCT06455449
active not recruiting Phase III Oncology
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Trial comparing a biosimilar copy of Keytruda with the original drug in advanced lung cancer patients to confirm equivalent effectiveness.
21 Apr 2026 NCT06311721
active not recruiting Phase III Gastroenterology
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn’s Disease
Guselkumab (IL-23 inhibitor) tested for treating perianal fistulas in Crohn's disease patients, measuring effectiveness and safety.
21 Apr 2026 NCT05347095
● Recruiting Phase III Oncology
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen…
21 Apr 2026 NCT06952803
● Recruiting Phase III Neurology
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer’s Disease (ADEPT-5)
The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.
21 Apr 2026 NCT06947941
● Recruiting Phase III Respiratory / COPD / Asthma
Randomised Evaluation of COVID-19 Therapy
RECOVERY is a randomised trial of treatments to prevent death in patients hospitalised with pneumonia. The treatments being investigated are: COVID-19: Lopinavir-Ritonavir, Hydroxychloroquine, Corticosteroids,…
21 Apr 2026 NCT04381936
● Recruiting Phase III Oncology
AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
The purpose of this study is to measure the efficacy and safety of R-mini-CHOP × 2 followed by AZD0486 compared with R-mini-CHOP × 6…
21 Apr 2026 NCT07215585
● Recruiting Phase III Oncology
SUPRAME-ACTengine® IMA203 vs. Investigator’s Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
This clinical trial is a prospective, multicenter, open-label, randomized, actively controlled, parallel-group Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of…
21 Apr 2026 NCT06743126
active not recruiting Phase III Cardiology / Cardiovascular
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) – ACCLAIM-Lp(a)
Lepodisiran injection reduces heart attacks and strokes in patients with high lipoprotein(a) levels and existing heart disease.
20 Apr 2026 NCT06292013
● Recruiting Phase III Oncology
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
Pfizer MEVPRO-1 (C2321014) is a randomized, open-label, multi-center clinical trial evaluating whether combining the study medicine (PF-06821497) with enzalutamide is safe and effective compared…
20 Apr 2026 NCT06551324
● Recruiting Phase III Oncology
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal…
20 Apr 2026 NCT04862663
● Recruiting Phase III Respiratory / COPD / Asthma
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single…
20 Apr 2026 NCT04910269
● Recruiting Phase III Oncology
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a…
20 Apr 2026 NCT07472517
● Recruiting Phase III Oncology
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
The primary objectives are to compare progression-free survival (PFS) and overall survival (OS) in participants who receive sotorasib with platinum doublet chemotherapy versus participants…
20 Apr 2026 NCT05920356
active not recruiting Phase III Diabetes / Metabolic
Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)
Weekly semaglutide injections tested against placebo over 5 years to see if it helps fatty liver disease.
17 Apr 2026 NCT04822181
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
What is being tested: Finerenone (a non-steroidal mineralocorticoid receptor antagonist) efficacy, safety, and pharmacokinetics in children with heart failure and left ventricular systolic dysfunction,…
17 Apr 2026 NCT07188805
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Treatment being tested: Finerenone (a non-steroidal mineralocorticoid receptor antagonist) in combination with ACE inhibitors or angiotensin receptor blockers in children with chronic kidney disease…
17 Apr 2026 NCT05196035
● Recruiting Phase III Cardiology / Cardiovascular
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
What is being tested: Orforglipron, a once-daily treatment, is being evaluated for its efficacy and safety in managing Fontaine II peripheral arterial disease (symptomatic…
17 Apr 2026 NCT07223593
● Recruiting Phase III Cardiology / Cardiovascular
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
What is being tested: AZD0780, an oral PCSK9 inhibitor, is being evaluated in a Phase III randomized controlled trial to assess its efficacy in…
17 Apr 2026 NCT07000357
● Recruiting Phase III Cardiology / Cardiovascular
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
What is being tested: Orforglipron (LY3502970), a GLP-1 receptor agonist, is being evaluated for its effects on cardiovascular outcomes compared to placebo over approximately…
17 Apr 2026 NCT07241390
● Recruiting Phase III Oncology
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Intervention being tested: Vepugratinib (LY3866288), a novel therapeutic agent, is being evaluated against placebo in a randomised controlled trial to assess safety, tolerability, and…
17 Apr 2026 NCT07218380
● Recruiting Phase III Oncology
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
A new drug combination tested against standard treatment in older adults with newly diagnosed acute lymphoblastic leukaemia.
16 Apr 2026 NCT04994717
active not recruiting Phase III Dermatology
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
Elranatamab injections compared to lenalidomide tablets for newly diagnosed myeloma patients after stem cell transplant.
16 Apr 2026 NCT05317416
active not recruiting Phase III
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
New drug combination (sonrotoclax plus zanubrutinib) tested against standard treatment (venetoclax plus obinutuzumab) for chronic lymphocytic leukaemia.
16 Apr 2026 NCT06073821
● Recruiting Phase III
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Researchers tested whether a new migraine drug (BHV-3000) works better than placebo for treating severe migraines in young people.
16 Apr 2026 NCT04649242
● Recruiting Phase III
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
CSL222 Trial Summary CSL222 gene therapy tested in teenage boys with moderate-to-severe hemophilia B for safety, tolerability, and effectiveness.
16 Apr 2026 NCT07080905
active not recruiting Phase III Oncology
A Study to Learn More About How Well Elinzanetant Works and How Safe it is Compared to Placebo for the Treatment of Hot Flashes Caused by Anti-cancer Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer
Elinzanetant reduces hot flashes from cancer therapy in breast cancer patients better than placebo.
16 Apr 2026 NCT05587296
active not recruiting Phase III Oncology
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Patients benefiting from olaparib in previous cancer trials can continue receiving it under this extension study.
16 Apr 2026 NCT04421963
● Recruiting Phase III
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
The primary objective of this study to evaluate efficacy of ravulizumab compared with placebo on proteinuria reduction and change in eGFR in adult participants…
16 Apr 2026 NCT06291376